Can you name the Exam 7 Drugs? by nberlon

Mechanism	Drug	Disease or Use
Inhibits VLDL synthesis raising HDL - largest increase in HDL, small reduction in LDL, larger reduction in triglycerides		Hypercholesterolemia (esp. with low HDL)
Inhibits angiotensin-converting enzyme (ACE), arterial vasodilation, reverses cardiac and arterial remodeling, reduced aldosterone secretion		Hypertension (primary drug in cases of diabetes, post-MI, and chronic renal disease), post-MI prophylaxis against the development of congestive heart failure, systolic and diastolic congestive heart failure
Accelerates inactivation of factor Xa		Venous thromboembolism, cardiac vascular surgery, treatment of MI and unstable angina
Sources of NO in vascular smooth muscle, dilation of veins more than arteries, dilation of large not small coronary arteries		Stable and unstable angina, acute decompensated congestive heart failure (nitroglycerin patch), acute MI (IV)
Activates A1 receptors in AV node, slows conduction in the AV node, increases the effective refractory period in the AV node		Terminates acute supraventricular tachyarrythmias
α1 receptor antagonist, vasodilation		Second-line hypertension (esp. in persons with high LDL and low HDL)
AT1 receptor antagonist (ARB), otherwise same as Lisinopril		Same as Lisinopril
Prevent binding of fibrinogen to thrombin		Thrombolytic therapy, heparin-induced thrombocytopenia
Source of NO + inhibitor of ROS production dilation of veins more than arteries, anti-remodeling activity		Congestive heart failure (African-Americans)
Block sodium channels in collecting duct		Prevent hypokalemia during diuretic therapy
Blocks sodium channels, stabilizes inactivated state of sodium channels, slows conduction in the ventricles, increases the effective refractory period in the ventricles		Terminates acute ventricular tachyarrhythmias
Inhibits sodium-potassium ATPase resulting in greater delivery of calcium to the contractile apparatus of cardiomyocytes, increases activity in the vagus nerve, slows conduction an		Systolic congestive heart failure, supraventricular tachyarrythmias
Monoclonal antibody directed against GPIIb/IIIa receptor, inhibition of platelet aggregation		Prevention of reocclusion after treatment of MI
Inhibits the carboxylation of glutamate residues in Vitamin K-dependent clotting factors		Venous thromboembolic diseases, primary prevention of thromboembolism from atrial fibrillation, and others
Blocks intestinal transport of cholesterol, modest reduction in LDL, no change in HDL		Hypercholesterolemia
Blockers of GPIIb/IIIa receptor, inhibition of platelet aggregation		Prevention of reocclusion after treatment of MI
Block cardiac and vascular L-type calcium channels, stabilize inactivated state of those calcium channels, arterial vasodilation, reduce inotropy and chronotropy, reduce myocardial		Stable angina (as alternative to beta blocker esp. in persons with persistent asthma), diastolic congestive heart failure (as alternative to beta blocker esp. in persons with persistent asthma), supraventricular tachyarrhythmias
α1β antagonist, reduces inotropy and chronotropy, vasodilation, anti-oxidant, anti-apoptotic activity		Hypertension (esp. with hyperlipidemia or diabetes), systolic congestive heart failure, diastolic congestive heart failure, stable angina
Cleave fibrin to resolve clot		Acute myocardial infarction, acute ischemic stroke, acute pulmonary embolism, and others
Blocks vascular L-type calcium channels, stabilizes inactivated state of those calcium channels, reduces myocardial oxygen demand, arterial vasodilation		Hypertension (usually as third drug or as second drug in isolated systolic hypertension), stable angina (as adjunct to nitrate + beta blocker), primary drug for variant angina

Mechanism	Drug	Disease or Use
Block potassium channels, varying effects on sodium and calcium channels, inhibit repolarization in the atria and ventricles		Prevent cardiac tachyarrythmias, terminate acute ventricular cardiac tachyarrythmias
β1 antagonist/increases NO availability, reduces inotropy and chronotropy, vasodilation, anti-remodeling activity		Hypertension (esp. in persons who experience exercise intolerance or sexual dysfunction when treated with another beta blocker), diastolic congestive heart failure, stable angina
Blocks the pacemaker channel in the SA node (HCN4), reduces heart rate without affecting inotropy or blood pressure, reduces myocardial oxygen demand		Stable angina
Irreversible cyclo-oxygenase (1 and 2) inhibition; inhibition of platelet activation		Arterial thrombotic diseases, primary prevention of arterial thrombi
β1-selective antagonists, reduce inotropy and chronotropy, reduce myocardial oxygen demand, slow conduction and increase refractoriness in AV node, reverse cardiac and arterial re		Hypertension ( although being downgraded for this use), stable and unstable angina, diastolic congestive heart failure, supraventricular tachyarrythmias
Non-selective β receptor antagonist, blocks potassium channels, slows conduction in the AV node, increases the effective refractory period in the AV node, inhibits repolarization		Prevents cardiac tachyarrhythmias
Inhibit HMGCoA reductase, greatest reduction in LDL, little increase in HDL		Hypercholesterolemia
Activate PPARα leading to increased lipoprotein lipase activity, reduced triglyceride synthesis, increased β-oxidation of fatty acids, small reduction in LDL, larger reduction in		Hypercholesterolemia
Thrombin inhibitors		High-risk angioplasty and heparin-induced thrombocytopenia (argatroban), primary prevention of thromboembolism from atrial fibrillation (dabigatran)
Accelerates inactivation of thrombin (factor IIa)		Venous thromboembolism, cardiac vascular surgery, treatment of MI and unstable angina
Increases osmolarity of extracellular fluid, washes out countercurrent multiplier		Rapid excretion of renal toxins and other toxins, cerebral edema, acute angle closure glaucoma
Mineralocorticoid (aldosterone) receptor antagonists		Prevent hypokalemia during diuretic therapy, congestive heart failure, post-myocardial infarction prophylaxis against the development of congestive heart failure
Antagonists of P2T purinergic receptor; inhibition of platelet aggregation		Prevention of arterial thrombi, especially after treatment of MI
Blocks potassium channels, inhibits repolarization in the atria and ventricles		Prevent cardiac tachyarrhythmias
Inhibit sodium-chloride cotransport in distal tubule (elimination of Na+ and water), direct arterial vasodilation (reduced blood pressure)		Primary drug for hypertension in most cases, mild congestive heart failure
Bind bile acids in intestine, modest reduction in LDL, little increase in HDL		Hypercholesterolemia
Inhibition of cyclic nucleotide phosphodiesterase; inhibition of platelet activation		Arterial thrombotic diseases (in combination)
Blocks late sodium channel, reduces inotropy without affecting heart rate or blood pressure, reduces myocardial oxygen demand		Stable angina
Inhibits NKCC2 cotransporter in thick ascending limb, stimulates NO/prostaglandin synthesis in veins, renal afferent arteriole, and to a lesser extent in other arteries, dilation o		Acute decompensated and chronic congestive heart failure, chronic renal insufficiency

Javascript is not currently enabled on your browser.
If you do have Javascript enabled:
This site uses javascript to make the magic happen.
Please turn on javascript and reload this page, or use a more current browser (like Firefox)